WSGR logoWSGR logo
Sara M. Butterfield
Patent Agent
Patents and Innovations

D858-350-2320

Download vCard
Open PDF

Dr. Sara Butterfield is a patent agent in the patents and innovations group of Wilson Sonsini Goodrich & Rosati. She has over a decade of experience in various aspects of intellectual property, including patent prosecution and freedom to operate, patentability, and diligence analyses. With a broad background at the interface of chemistry and biology, Sara represents clients in a range of areas, including biotech, antibody, pharmaceutical, and small molecule technologies.

Prior to joining the firm, Sara worked as a patent agent for several years in law firms in the Chicago area. After obtaining a Ph.D. in organic chemistry from UNC Chapel Hill, she worked as a postdoctoral assistant at the Skaggs Institute for Chemical Biology at the Scripps Research Institute. She later moved abroad and worked as a scientist at the Swiss Federal Institute of Lausanne, where her research focused on the molecular mechanisms involved in protein aggregation events related to Parkinson’s disease. Sara has laboratory experience in peptide chemistry, protein folding, synthetic organic chemistry, liposome-based colorimetric/fluorometric assay development, and techniques such as one- and two-dimensional NMR, chromatography, and electrophoresis. 

Experience

Dr. Sara Butterfield is a patent agent in the patents and innovations group of Wilson Sonsini Goodrich & Rosati. She has over a decade of experience in various aspects of intellectual property, including patent prosecution and freedom to operate, patentability, and diligence analyses. With a broad background at the interface of chemistry and biology, Sara represents clients in a range of areas, including biotech, antibody, pharmaceutical, and small molecule technologies.

Prior to joining the firm, Sara worked as a patent agent for several years in law firms in the Chicago area. After obtaining a Ph.D. in organic chemistry from UNC Chapel Hill, she worked as a postdoctoral assistant at the Skaggs Institute for Chemical Biology at the Scripps Research Institute. She later moved abroad and worked as a scientist at the Swiss Federal Institute of Lausanne, where her research focused on the molecular mechanisms involved in protein aggregation events related to Parkinson’s disease. Sara has laboratory experience in peptide chemistry, protein folding, synthetic organic chemistry, liposome-based colorimetric/fluorometric assay development, and techniques such as one- and two-dimensional NMR, chromatography, and electrophoresis. 

Focus Areas
Recent Insights
Client Highlights
Wilson Sonsini Advises Janux Therapeutics on IP Matters Related to $296.5 Million Underwritten Public Offering
On February 29, 2024, Janux Therapeutics (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, announced the pricing of an underwritten public offering of 4,440,851 shares of its common stock at a public offering price of $46.50 per share and pre-funded warrants to purchase 1,935,483 shares of common stock at a price of $46.499 per pre-funded warrant, which represents the per share price for the common stock less the $0.001 per share exercise price for each such pre-funded warrant. The aggregate gross proceeds to Janux from the offering, before deducting underwriting discounts and commissions and other estimated offering expenses and excluding the exercise of any pre-funded warrants, are expected to be approximately $296.5 million. In addition, Janux has granted the underwriters a 30-day option to purchase up to an additional 956,450 shares of its common stock. All of the shares to be sold in the offering are to be sold by Janux. The offering is expected to close on or about March 4, 2024, subject to customary closing conditions. Janux intends to use the net proceeds from the offering to advance clinical development of its internal product pipeline and for general corporate purposes.
Learn More
Client Highlights
Firm Advises Foresite Capital on IP Matters Related to CG Oncology Financing
On August 2, 2023, CG Oncology, Inc., an oncolytic immunotherapy company focused on developing bladder-saving therapeutics for patients with urologic cancer, announced the close of an oversubscribed $105 million crossover financing round, co-led by new investors Foresite Capital and TCGX, with participation from Avidity Partners, BVF Partners, and Janus Henderson Investors, as well as existing investors including Acorn Bioventures, Ally Bridge Group, Decheng Capital, Longitude Capital, Malin Corporation, and RA Capital Management. Wilson Sonsini Goodrich & Rosati advised Foresite Capital on IP matters related to the transaction.
Learn More
View All
WSGR logo
Copyright © 2024 Wilson Sonsini Goodrich & Rosati. All Rights Reserved.